Its activity in renal cancer was tested in a phase II trial comparing lenvatinib alone, lenvatinib in combination with everolimus, and everolimus alone in metastatic or locally advanced mRCC patients who progressed after VEGF-TKI therapy (Motzer et al. 2015a, b). Here, VEGFA is linked to renal carcinoma.